The Arizona Diamondbacks just added a veteran outfielder who cannot play until late June and is coming off both a down year and a performance-enhancing drug suspension. It is the kind of bargain-bin gamble that is smarter than it first looks, with one real complication.
Kepler signed with Arizona while still serving his suspension, and June 25 is the first day he is eligible to play in 2026, giving him a couple of weeks of minor league ramp-up before debuting for the Diamondbacks.
The bet is cheap, which is the point
Financial terms were not disclosed, but a player in this situation signs for a small guaranteed salary prorated over the rest of the season.
That is the appeal. Arizona is risking almost nothing on a veteran with real big-league pedigree, and modest production would make it found value for a contending roster. If he does not produce, the team walks away having spent next to nothing.
The catch the upside has to clear
Kepler was not good before the suspension. He hit .216/.300/.391 with 18 home runs over 474 plate appearances last year, numbers that now carry the added cloud of a PED penalty.
The uncomfortable question with any post-suspension signing is how much of the prior production was the player and how much was chemically assisted, and there is no clean way to answer it until he plays without the help. Arizona is buying a reclamation project.
Why it still makes sense
Contenders are always hunting for cheap upside on the margins, and a left-handed bat with power and a track record fits that mold even with the baggage.
The Diamondbacks are not betting that Kepler returns to form. They are betting the cost is low enough that they do not need him to. If the ramp-up goes smoothly, he debuts in late June as a depth piece who cost almost nothing, which is how smart teams shop the bargain bin with their eyes open.
Discover more from NAIRAVOICE.COM.NG
Subscribe to get the latest posts sent to your email.
